SCHEMBL2201905

SCHEMBL2201905

CCOC(=O)c1nn(C)c(-c2cccc(Br)c2)c1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 3/20 0.52
ELANE P08246 4/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
CACNA1F O60840 1/20 0.45
ABCB1 P08183 1/20 0.45
CACNA1D Q01668 1/20 0.45
CACNA1S Q13698 1/20 0.45
CACNA1C Q13936 1/20 0.45
MAPT P10636 4/20 0.45
ALDH1A1 P00352 2/20 0.45
MAPK1 P28482 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ALOX5 P09917 3/20 0.43
PTGES O14684 1/20 0.43
GRM5 P41594 1/20 0.43
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
THRB P10828 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18355564 0.85 JAK2 (0.49) ELANENPC1RAB9AMAPTALDH1A1
SCHEMBL10057637 0.84 ALDH1A1 (0.55) CYP19A1NPC1RAB9AMAPTALDH1A1
SCHEMBL2202109 0.83 GRM5 (0.48) NPC1RAB9AALDH1A1SMN1; SMN2GRM5
SCHEMBL2201365 0.81 CACNA1F (0.47) CYP19A1ELANENPC1RAB9ACACNA1F
SCHEMBL15884068 0.81 GABRG2 (0.47) CYP19A1ELANENPC1MAPTALDH1A1
SCHEMBL16883790 0.79 NPC1 (0.53) ELANENPC1RAB9AMAPTALDH1A1
SCHEMBL15884141 0.79 KCNB1 (0.43) GRM5
SCHEMBL2203141 0.77 MAPT (0.48) NPC1RAB9AMAPTALDH1A1MAPK1
SCHEMBL3603486 0.77 GRM5 (0.56) NPC1RAB9AALDH1A1GRM5
SCHEMBL5023771 0.77 CNR1 (0.55) CYP19A1ELANENPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206136-B2 Pyrazolyl-based carboxamides I Grünenthal GmbH (DE) 2015-12-08 US disclosed
US-9206136-B2 Pyrazolyl-based carboxamides I Grünenthal GmbH (DE) 2015-12-08 US disclosed
WO-2014108337-A1 PYRAZOLYL-BASED CARBOXAMIDES I AS CRAC CHANNEL INHIBITORS Grünenthal GmbH (DE) 2014-07-17 WO disclosed
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
EP-2182953-A2 NEW PYRAZOL DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-05-12 EP disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
WO-2009013211-A2 NEW PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029963-A1 PYRAZOL DERIVATIVES CCR1, CCR3, CCRL2 CYP19A1 3117/4885ELANE 791/4885NPC1 1547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.